A review of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy
Open accessAbstract
Convalescent plasma (CP) therapy is rapidly becoming an established consideration in the treatment of COVID-19 patients though there is a need to critically review this area for proof of efficacy. Neutralizing antibodies (NAb) present in CP generated in response to SARS-CoV-2 infection directed against the receptor-binding domain (RBD) of the spike protein are considered to play main role in viral clearance. CP infusion may also help in the modulation of immune response by its immunomodulatory effect. The FDA allows for administration of CP to COVID-19 patients. The present published literature in COVID-19 is limited to case series and randomised controlled trial where plasma therapy was used in moderate, severe and critically ill patients. Though multiple uncertainties exist regarding to its efficacy, appropriate donor selection and NAb titres, the efficacy data of CP use inCOVID-19 is limited having shown hope with early and severe to critically ill COVID-19 patients.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Convalescent patient serum samples have provided promising results in the clinic.
“Convalescent patient serum samples have also provided promising results in the clinic151.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [151]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586 · see citing works
Peiris, J., Chu, C., Cheng, V., Chan, K., Hung, I., Poon, L., Law, K., Tang, B., Hon, T., Chan, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13412-5 · Cited by 2,375 · see citing works
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, L., et al. (2020) · JAMA · doi:10.1001/jama.2020.4783 · Cited by 2,278 · see citing works
Effectiveness of convalescent plasma therapy in severe COVID-19 patients
Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., Zhou, M., Chen, L., Meng, S., Hu, Y., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004168117 · Cited by 1,962 · see citing works
McGonagle, D., Sharif, K., O'Regan, A., & Bridgewood, C. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102537 · Cited by 1,654 · see citing works
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419 · see citing works
Li, L., Zhang, W. J., Hu, Y., Tong, X., Zheng, S., Yang, J., Kong, Y., Ren, L., Wei, Q., Mei, H., et al. (2020) · JAMA · doi:10.1001/jama.2020.10044 · Cited by 1,207 · see citing works
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., et al. (2020) · Science · doi:10.1126/science.abd7728 · Cited by 1,195 · see citing works
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
(2020) · Science · doi:10.1101/2020.07.14.20151126 · Cited by 1,192 · see citing works
Mair-Jenkins, J., Saavedra-Campos, M., Baillie, J. K., Cleary, P. R., Khaw, F.-M., Lim, W. S., Makki, S., Rooney, K., Convalescent Plasma Study Group, Nguyen‐Van‐Tam, J. S., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu396 · Cited by 985 · see citing works
Use of convalescent plasma therapy in SARS patients in Hong Kong
Cheng, Y., Wong, R. S. M., Soo, Y. O. Y., Wong, W. S., Lee, C. K., Ng, M. H. L., Chan, P. K. S., Wong, K. C., Leung, C. B., & Cheng, G. Y.-M. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1271-9 · Cited by 953 · see citing works
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
Simonovich, V., Pratx, L. D. B., Scibona, P., Beruto, V., Vallone, M. G., Vázquez, C., Savoy, N., Giunta, D. H., Pérez, L. G., Sanchez, M. D. L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2031304 · Cited by 907 · see citing works
Liu, L., Wei, Q., Lin, Q., Fang, J., Wang, H., Kwok, H., Tang, H., Nishiura, K., Peng, J., Tan, Z., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.123158 · Cited by 830 · see citing works
Deployment of convalescent plasma for the prevention and treatment of COVID-19
Bloch, E. M., Shoham, S., Casadevall, A., Sachais, B. S., Shaz, B. H., Winters, J. L., van Buskirk, C. M., Grossman, B. J., Joyner, M. J., Henderson, J. P., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138745 · Cited by 798 · see citing works
Wu, F., Wang, A., Liu, M., Wang, Q., Chen, J., Xia, S., Ling, Y., Zhang, Y., Xun, J., Lu, L., et al. (2020) · doi:10.1101/2020.03.30.20047365 · Cited by 754 · see citing works
Agarwal, A., Mukherjee, A., Kumar, G., Chatterjee, P., Bhatnagar, T., Malhotra, P., & Collaborators, P. T. (2020) · BMJ · doi:10.1136/bmj.m3939 · Cited by 718 · see citing works
Hung, I. F., To, K. K., Lee, C. K., Lee, K., Chan, K., Yan, W.-W., Liu, R. W., Watt, C., Chan, W.-M., Lai, K., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq106 · Cited by 679 · see citing works
Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis
Gralinski, L. E., Sheahan, T. P., Morrison, T. E., Menachery, V. D., Jensen, K., Leist, S. R., Whitmore, A. C., Heise, M. T., & Baric, R. S. (2018) · mBio · doi:10.1128/mbio.01753-18 · Cited by 656 · see citing works
Early safety indicators of COVID-19 convalescent plasma in 5000 patients
Joyner, M. J., Wright, R. S., Fairweather, D., Senefeld, J. W., Bruno, K. A., Klassen, S. A., Carter, R. E., Klompas, A. M., Wiggins, C. C., Shepherd, J. R. A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci140200 · Cited by 472 · see citing works
Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins
Wang, S., Tseng, S., Yen, C., Yang, J.-Y., Tsao, C.-H., Shen, C.-W., Chen, K.-H., Liu, F., Liu, W.-T., Chen, Y. A., et al. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.090 · Cited by 421 · see citing works
Zhang, B., Liu, S., Tan, T., Huang, W., Dong, Y., Chen, L., Chen, Q., Zhang, L., Zhong, Q., Zhang, X., et al. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.03.039 · Cited by 421 · see citing works
Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infectionPreprint
Seow, J., Graham, C., Merrick, B., Acors, S., Steel, K., Hemmings, O., O'Bryne, A., Kouphou, N., Pickering, S., Rui, G.-L. P., et al. (2020) · medRxiv · doi:10.1101/2020.07.09.20148429 · Cited by 411 · see citing works
Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes
Monsalvo, A. C., Batalle, J. P., López, M. G., Krause, J. C., Klemenc, J. M., Hernandez, J. Z., Maskin, B. C., Bugna, J., Rubinstein, C. J., Aguilar, L., et al. (2010) · Nature Medicine · doi:10.1038/nm.2262 · Cited by 263 · see citing works
Klassen, S. A., Senefeld, J. W., Johnson, P. W., Carter, R. E., Wiggins, C. C., Shoham, S., Grossman, B. J., Henderson, J. P., Musser, J. M., Salazar, E., et al. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.02.008 · Cited by 225 · see citing works
Salazar, E., Kuchipudi, S. V., Christensen, P. A., Eagar, T. N., Yi, X., Zhao, P., Jin, Z., Long, S. W., Olsen, R. J., Chen, J., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci141206 · Cited by 213 · see citing works
Arabi, Y. M., Balkhy, H. H., Hajeer, A. H., Bouchama, A., Hayden, F. G., Al‐Omari, A., Al-Hameed, F. M., Taha, Y., Shindo, N., Whitehead, J., et al. (2015) · SpringerPlus · doi:10.1186/s40064-015-1490-9 · Cited by 202 · see citing works
Zhang, L., Zhang, F., Yu, W., Tian, H., Yu, J., Yi, C. E., Ba, L., Li, W., Farzan, M., Chen, Z., et al. (2005) · Journal of Medical Virology · doi:10.1002/jmv.20499 · Cited by 184 · see citing works
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review
Valk, S. J., Piechotta, V., Chai, K. L., Doree, C. J., Monsef, I., Wood, E. M., Lamikanra, A., Kimber, C., McQuilten, Z., So‐Osman, C., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013600 · Cited by 180 · see citing works
Abe, Y., Horiuchi, A., Miyake, M., & Kimura, S. (1994) · Immunological Reviews · doi:10.1111/j.1600-065x.1994.tb00854.x · Cited by 161 · see citing works
Treatment for emerging viruses: Convalescent plasma and COVID-19
Brown, B., & McCullough, J. (2020) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2020.102790 · Cited by 161 · see citing works
Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 PatientsPreprint
Joyner, M. J., Wright, R. S., Fairweather, D., et al. (2020) · medRxiv · doi:10.1101/2020.05.12.20099879 · Cited by 128 · see citing works
Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone
Sahr, F., Ansumana, R., Massaquoi, T. A., Idriss, B. R., Sesay, F. R., Lamin, J. M., Baker, S., Nicol, S., Conton, B., Johnson, W. R., et al. (2016) · Journal of Infection · doi:10.1016/j.jinf.2016.11.009 · Cited by 121 · see citing works
Evidence favouring the efficacy of convalescent plasma for COVID-19 therapyPreprint
Joyner, M. J., Klassen, S. A., Senefeld, J. W., et al. (2020) · medRxiv · doi:10.1101/2020.07.29.20162917 · Cited by 89 · see citing works
To, K. K., Zhang, J., Hung, I. F., Xu, T., Ip, W. C., Wong, R. T. Y., Ng, J. C. K., Chan, J. F., Chan, K., & Yuen, K. (2012) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00081-12 · Cited by 83 · see citing works
Salazar, E., Kuchipudi, S., Christensen, P. A., et al. (2020) · bioRxiv · doi:10.1101/2020.06.08.138990 · Cited by 82 · see citing works
Tjon, A. S. W., van Gent, R., Jaadar, H., van Hagen, P. M., Mancham, S., van der Laan, L. J. W., Boekhorst, P. A. W. T., Metselaar, H. J., & Kwekkeboom, J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301260 · Cited by 61 · see citing works
Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis
Wang, M., Wu, T., Zuo, Z., You, Y., Yang, X., Pan, L., Hu, Y., Luo, X., Jiang, L., Xia, Z., et al. (2020) · BMJ Supportive & Palliative Care · doi:10.1136/bmjspcare-2020-002554 · Cited by 45 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- [8]Wajnberg A, Amanat F, Firpo A, Altman D, Bailey M, Mansour M, et al. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. medRxiv. 2020.
- [34]Kulkarni R Bramhachari PV Antibody-dependent enhancement of viral infections BT-dynamics of immune activation in viral diseases Dyn. Immune Act. Viral Dis Singapore 2020 Singapore Springer 9 41
Cited by
Sorted by citations
SARS-CoV-2, COVID-19 and the aging immune system
Bartleson, J. M., Radenkovic, D., Covarrubias, A. J., Furman, D., Winer, D. A., & Verdin, E. (2021) · Nature Aging · doi:10.1038/s43587-021-00114-7 · Cited by 359 · see citing works
Immunosenescence and inflamm-ageing in COVID-19
Zinatizadeh, M. R., Zarandi, P. K., Ghiasi, M., Kooshki, H., Mohammadi, M., Amani, J., & Rezaei, N. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101818 · Cited by 62 · see citing works
Liver injury, SARS‐COV‐2 infection and COVID‐19: What physicians should really know?
Licata, A., Minissale, M. G., Distefano, M., & Montalto, G. (2021) · GastroHep · doi:10.1002/ygh2.455 · Cited by 21 · see citing works
Batista, C. M., & Foti, L. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108036 · Cited by 16 · see citing works
Gül, F., Gönen, Z. B., Jones, O. Y., Taşlı, P. N., Zararsız, G., Ünal, E., Özdarendeli, A., Şahi̇n, F., Eken, A., Yılmaz, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.963309 · Cited by 16 · see citing works
Heterologous SARS‐CoV ‐2 IgA neutralising antibody responses in convalescent plasma
Davis, S. K., Selva, K. J., López, E., Haycroft, E. R., Lee, W. S., Wheatley, A. K., Juno, J. A., Adair, A., Pymm, P., Redmond, S. J., et al. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1424 · Cited by 14 · see citing works
The Immunopathobiology of SARS-CoV-2 Infection
Patel, M., Shahjin, F., Cohen, J. D., Hasan, M., Machhi, J., Chugh, H., Singh, S., Das, S., Kulkarni, T. A., Herskovitz, J., et al. (2021) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuab035 · Cited by 14 · see citing works
A Potential Role of the CD47/SIRPalpha Axis in COVID-19 Pathogenesis
McLaughlin, K.-M., Bojková, D., Kandler, J. D., Bechtel, M., Reus, P., Le, T. T., Rothweiler, F., Wagner, J. U. G., Weigert, A., Ciesek, S., et al. (2021) · Current Issues in Molecular Biology · doi:10.3390/cimb43030086 · Cited by 12 · see citing works
Stein, D., Oviedo‐Orta, E., Kampman, W., McGinniss, J., Betts, G., McDermott, M., Holly, B., Lancaster, J. M., Braunstein, N. S., Yancopoulos, G. D., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1059 · Cited by 12 · see citing works
Cava, C., Bertoli, G. R., & Castiglioni, I. (2021) · Future Virology · doi:10.2217/fvl-2020-0392 · Cited by 11 · see citing works
Antibody Therapy: From Diphtheria to Cancer, COVID-19, and Beyond
Kumar, D., Gauthami, S., Bayry, J., Kaveri, S. V., & Hegde, N. R. (2021) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2021.0004 · Cited by 10 · see citing works
Convalescent Plasma Transfusion for the Treatment of COVID-19 in Adults: A Global Perspective
Kanj, S., & Al‐Omari, B. (2021) · Viruses · doi:10.3390/v13050849 · Cited by 7 · see citing works
Biopharmaceuticals for prevention of COVID-19
Farjami, A., Montazersaheb, S., Soofiyani, S. R., Akbarzadehlaleh, P., & Salatin, S. (2022) · Asian Pacific Journal of Tropical Medicine · doi:10.4103/1995-7645.348158 · Cited by 5 · see citing works
Morshed, M. S., Mosabbir, A. A., & Hossain, M. S. (2023) · Bangladesh Journal of Microbiology · doi:10.3329/bjm.v39i1.64052 · Cited by 3 · see citing works
CD47 as a potential biomarker for the early diagnosis of severe COVID-19Preprint
McLaughlin, K.-M., Bojková, D., Bechtel, M., Kandler, J. D., Reus, P., Le, T. T., Wagner, J. U. G., Ciesek, S., Wass, M. N., Michaelis, M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.01.433404 · Cited by 2 · see citing works
Anwer, Z. M., Yahya, R. N., & Mubder, N. (2022) · Iraqi Journal of Pharmaceutical Sciences · doi:10.31351/vol31iss2pp223-232 · Cited by 1 · see citing works
Sabaz, M. S., Gül, F., Bilgili, B., Kaplan, S. T., Oktay, B. D., & Cinel, İ. (2022) · Türk yoğun bakım derneği dergisi/Türk yoğun bakım dergisi · doi:10.4274/tybd.galenos.2022.63634
- Authors
- Devarasetti, P. K., Rajasekhar, L., Baisya, R., Sreejitha, K. S., & Vardhan, Y. K.
- Affiliations
- Nizam's Institute of Medical Sciences (IN)
- Corresponding author
- Rajasekhar, Liza
- Venue
- Immunologic Research
- Published
- 2021-01-25
- Volume
- 69
- Issue
- 1
- Pages
- 18-25
- ISSN
- 0257-277X (ISSN-L)
- 1559-0755
- PMC
- PMC7829318
- OpenAlex
- W3122105882
- Cited by
- 17
- References
- 33
- Citations by year
- 2023: 1 · 2022: 6 · 2021: 10
- FWCI
- 0.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Immunologic Research (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Neurology › Long-Term Effects of COVID-19
- Keywords
- COVID-19 pandemic, convalescent plasma therapy, SARS-CoV-2, neutralizing antibodies, spike protein receptor-binding domain, immunomodulation, donor selection, treatment efficacy, critically ill patients
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Serotherapy, Humans, Immunization, Passive, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
